FIELD: chemistry.
SUBSTANCE: invention relates to imidazopyridines of formula I and to a pharmaceutically acceptable salt thereof, where Z1 is CR1; R1 is H; R1' is H; Z2 is CR2; Z3 is CR3; R2 and R3 are H; R4 is H; Y is W-C(O)-; W is or ; R5 is H; X1 is selected from R11' and -OR11'; R11 is independently H or C1-C6 alkyl, optionally substituted -(CR19R20)nCOR16; X4 is ; R6 is halogen, carbocyclyl or -(CR19R20)n-SR16, wherein said carbocyclyl is cyclopropyl or cyclobutyl; R6' is halogen; p equals 1, 2; n equals 0, 1; each R16 is independently H or C1-C6 alkyl; R19 and R20 are independently selected from H or C1-C6 alkyl. The invention also relates to a pharmaceutical composition based on the compound of formula I and a method of inhibiting anomalous cell growth or treating a hyperproliferative disorder, based on use of the compound of formula I.
EFFECT: obtaining novel imidazopyridine derivatives of formula I, which are useful in treating hyperproliferative disorders.
7 cl, 14 ex
Title | Year | Author | Number |
---|---|---|---|
5-ANILINOIMIDAZOPYRIDINES AND METHODS FOR USING THEM | 2008 |
|
RU2441004C1 |
AZABENZOTHIOPHENYL COMPOUNDS AND METHODS OF USE | 2007 |
|
RU2444524C2 |
BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | 2009 |
|
RU2509078C2 |
AZABENZOFURANYL COMPOUNDS AND METHODS OF USE | 2007 |
|
RU2448111C2 |
ISOINDOLONES AND METHODS FOR USING THEM | 2009 |
|
RU2495028C2 |
COMPOSITIONS FOR TREATING CANCER USING ANTAGONISTS WHICH BIND TO THE PD-1 SIGNALING PATHWAY COMPONENT AND MEK INHIBITORS | 2015 |
|
RU2733735C2 |
AZAINDOLIZINES AND METHODS FOR PREPARING THEM | 2008 |
|
RU2483069C2 |
DIAZACARBAZOLES AND METHODS OF APPLICATION | 2009 |
|
RU2515972C2 |
SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE FOR TREATMENT OF PATHOLOGICAL CONDITIONS | 2017 |
|
RU2773333C2 |
TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGUES AND USE THEREOF AS THERAPEUTIC AGENTS AND DIAGNOSTIC SAMPLES | 2009 |
|
RU2537945C2 |
Authors
Dates
2013-11-20—Published
2008-12-18—Filed